Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,881,000 | 5,365,000 | 4,787,000 | 4,725,000 | 3,836,000 |
| Depreciation Amortization | 1,669,000 | 1,348,000 | 1,386,000 | 1,336,000 | 1,056,000 |
| Income taxes - deferred | 986,000 | 1,045,000 | 947,000 | 959,000 | 844,000 |
| Accounts receivable | -446,000 | -311,000 | -395,000 | 49,000 | -15,000 |
| Accounts payable and accrued liabilities | -17,000 | 215,000 | 238,000 | 74,000 | 148,000 |
| Other Working Capital | -813,000 | -990,000 | -424,000 | -921,000 | -701,000 |
| Other Operating Activity | 490,000 | -108,000 | 14,000 | -993,000 | -810,000 |
| Operating Cash Flow | $7,750,000 | $6,564,000 | $6,553,000 | $5,229,000 | $4,358,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,684,000 | -788,000 | 471,000 | 429,000 | 1,529,000 |
| PPE Investments | -1,009,000 | -1,131,000 | -1,237,000 | -885,000 | -638,000 |
| Net Acquisitions | -8,536,000 | -645,000 | -272,000 | -542,000 | -101,000 |
| Purchase Of Investment | -510,000 | -740,000 | -946,000 | -2,573,000 | -3,901,000 |
| Sale Of Investment | 255,000 | 484,000 | 632,000 | 582,000 | 744,000 |
| Purchase Sale Intangibles | -52,000 | 4,000 | 121,000 | 124,000 | -405,000 |
| Other Investing Activity | -52,000 | 4,000 | 121,000 | 124,000 | -405,000 |
| Investing Cash Flow | $-7,168,000 | $-2,816,000 | $-1,231,000 | $-2,865,000 | $-2,772,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,903,000 | 683,000 | -265,000 | -390,000 | 192,000 |
| Debt Issued | 15,000 | 14,000 | 18,000 | 999,000 | 821,000 |
| Debt Repayment | -886,000 | -14,000 | -31,000 | -18,000 | -74,000 |
| Common Stock Issued | 67,000 | 60,000 | N/A | N/A | 2,416,000 |
| Common Stock Repurchased | -231,000 | -1,820,000 | -306,000 | -3,228,000 | -2,249,000 |
| Dividend Paid | -2,139,000 | -1,921,000 | -1,690,000 | -1,404,000 | -1,268,000 |
| Other Financing Activity | 0 | 0 | -3,458,000 | 0 | 0 |
| Financing Cash Flow | $-271,000 | $-2,998,000 | $-5,732,000 | $-4,041,000 | $-162,000 |
| Exchange Rate Effect | -94,000 | 56,000 | 258,000 | 836,000 | -156,000 |
| Beginning Cash Position | 6,083,000 | 5,646,000 | 5,798,000 | 6,639,000 | 5,371,000 |
| End Cash Position | 6,321,000 | 6,083,000 | 5,646,000 | 5,798,000 | 6,639,000 |
| Net Cash Flow | $238,000 | $437,000 | $-152,000 | $-841,000 | $1,268,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,750,000 | 6,564,000 | 6,553,000 | 5,229,000 | 4,358,000 |
| Capital Expenditure | -1,078,000 | -1,259,000 | -1,329,000 | -1,068,000 | -801,000 |
| Free Cash Flow | 6,672,000 | 5,305,000 | 5,224,000 | 4,161,000 | 3,557,000 |